{"name":"Innovacell GmbH","slug":"innovacell-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"aSMDC","genericName":"aSMDC","slug":"asmdc","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"aSMDC","genericName":"aSMDC","slug":"asmdc","phase":"phase_3","mechanism":"aSMDC is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPc1Q0ZENwUkozRU91dDVYV1pLSEN2b2w5VE80R1Y1MlFoZHJsX2FMSnc3WVZOZHlIamVYMTQxTlFqTDBvWl94dWdTd2xtckZJcE54Ml9oVXcyRTdqV01LeHJ3VDhveHdqLWtwSzB3MDNkZ1RwdjFmZDMwZDF4ekx2Ynl6YXFlejdlVUNlWDB6UHNVSHpfQU9wSmhTdG9LUG1ZenZTTQ?oc=5","date":"2026-02-24","type":"pipeline","source":"BioWorld News","summary":"Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies - BioWorld News","headline":"Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOTkxtZGhuYjNIZGdzQ2N6eWFTX05hcDVpcjRLUWI1ZmRSZHdIQkVOWmdUMll1RjUtVE00UzVFTWVGWUZvYkREeUdYMmNha0N4MmRMcFluRDIwaE4yWk55N3ozeDZva0JjQXFxRlluZ0RjbGNBQ3dwUmNvNEdjYk5wYktzWFZCcTcxcUNtUnZEUVVxMmJPeEtCQTRzZUU2cjBHSUdTZ3dHZzhfQURSVENsSWxCZDJ5Vl9pMkJDRWdHMUlhTzBQN3VhUXpOamhOck5fZVBpRExleVlUaHBseVB3?oc=5","date":"2025-01-28","type":"pipeline","source":"BRIDGE（ブリッジ）","summary":"Innovacell, Developer of Cell Therapy for Fecal and Urinary Incontinence, Raises 1.06 Billion Yen - BRIDGE（ブリッジ）","headline":"Innovacell, Developer of Cell Therapy for Fecal and Urinary Incontinence, Raises 1.06 Billion Yen - BRIDGE（ブリッジ）","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}